Best of ASCO - 2014 Annual Meeting

 

Welcome

Small Molecules

Developmental Therapeutics and Tumor Biology (Nonimmuno)

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A CRUK first-in-human phase I trial of a CDC7 Inhibitor, LY3143921 hydrate, in patients with advanced solid tumors.

Peter F. Gallagher

TPS3167

A dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of mTORC1/2 inhibitor XP-105 (BI 860585) as monotherapy and in combination with exemestane or paclitaxel in patients (pts) with advanced solid tumors.

Filippo G. De Braud

3127

A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).

Shubham Pant

3001

A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.

Drew W. Rasco

3125

A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.

Drew W. Rasco

3126

A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.

Xing Zhang

3124

A phase I, first-in-human, dose-escalation and dose-expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.

Sarina Anne Piha-Paul

TPS3168

Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.

April K.S. Salama

3002

Effect of GPR87 on cell proliferation via KRAS signaling pathway in p53-mutant lung cancer cells.

Takayuki Nakano

e14713

Effect of MALAT1 in the crosstalk between nucleus and mitochondria on mitochondrial reprogramming in hepatocellular carcinoma cells.

Yijing Zhao

e14711

Effect of tivantinib on VEGF signaling pathways and apoptosis of gastric cancer cells with c-MET or VEGFA amplification.

Hyeong Su Kim

e14719

FBXO4 as a novel ubiquitin ligase that targets Cyclin D in the pathogenesis of breast cancer.

Ruby Dhar

e14722

Impact of combined MRP1 inhibition and mutant p53-targeting compound APR-246.

Anna Sophia Ceder

e14712

Larotrectinib efficacy and safety in adult TRK fusion cancer patients.

David S. Hong

3122

Modulating the tumor microenvironment to enhance efficacy of PARP inhibitors.

Manal Mehibel

e14715

Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors.

Johanna C. Bendell

TPS3169

Phase 1b study of selinexor, a first-in-class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).

Eoghan Ruadh Malone

3123

Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.

Timothy A Yap

3014

Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.

D. Ross Camidge

3011

Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.

Isabel Arrillaga

3005

Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.

Joshua James Gruber

3006

Targeting EGFR Ex20 mutant lung cancer with the wild type sparing kinase inhibitor PRB001.

Martin L. Sos

e14718